- Home
- TVGN
as 03-25-2025 4:00pm EST
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 222.3M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 537.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $4.78 | Next Earning Date: | 04-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tevogen Bio Holdings Inc. Common Stock News
TVGN Breaking Stock News: Dive into TVGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
GlobeNewswire
19 days ago
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
GlobeNewswire
23 days ago
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
GlobeNewswire
a month ago
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
GlobeNewswire
a month ago
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
GlobeNewswire
a month ago
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
GlobeNewswire
a month ago
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
GlobeNewswire
a month ago
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
Compare TVGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVGN Tevogen Bio Holdings Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.